PolymarketComprobar disponibilidadSin KYCDatos de resolución verificadosBien calibradoAviso de calidad de datosSin cotizaciones en vivo
Datos del 5 oct 2026, 22:11 UTC · política pm-quality-4
Probabilidad implícita actual
June 30, 83%
June 30, 83%Calidad del mercado
≤49 / 100
Baja calidadVolumen 24h
—
Liquidez
7 mil €
Liquidez mediaCompra / Venta
82.0% / 83.0%
Spread
1.0 pt
Spread estrechoComentarios
0
Datos de mercado
Actualizado hace 5 minutos
19 ago 26, 18:47 UTC1 jul 27, 3:59 UTC
Tendencias
Condiciones de la plataforma
Fuente: Polymarket
Estas condiciones son informativas; las operaciones simuladas de CoinRithm siguen sus propias reglas.
- Orden mínima (participaciones):
- 5
- Incremento de precio:
- 1 puntos porcentuales
- Comisiones:
- Sí
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiReglas
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.